BETA
Your AI-Trained Oncology Knowledge Connection!
Between the Lines is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from academic and community oncologists on published, peer-reviewed content.
Anti-HER3 Antibodies May Inhibit Growth of Tumors Harboring NRG1 Fusions
Third-Line Treatment of HER2-Positive Advanced Breast Cancer: From No Standard to A Pandora’s Box